The first generic! Osekon Pharmaceuticals TPO-R agonisant is listed.

According to the latest public announcement by the Drug Review Center (CDE) of the State Drug Administration of China, Osekang Pharmaceuticals submitted an application for the listing of apopamatablet generic sashimi, classified as 4 categories, and was accepted on June 29Apoapa ethanolamine tablets are non-peptide oral platelet receptor (TPO-R) agonists, and only Novartis's Rifland (Apopa ethanolamine tablets) are approved for market in ChinaThe listing application by Oseikang Pharmaceuticals means that China is expected to welcome a generic version of apopa ethanolamine tabletas a non-peptide oral TPO receptor agonis, apopa ethanolamine tablets can bind to TPO receptors (trans membrane regions) on the cell membrane, activate signal transduction pathways, stimulate the differentiation and proliferation of human bone marrow progenitor cells to macronuclear cells, promote the maturation of macronuclear cells, thereby increasing platelet productionAt the same time, aiquupa ethanol amine tablets and endogenous TPO function site is different, will not compete with endogenous TPO receptors, so the two will not form competitive inhibition, and may be synergy, together to enhance platelet countNovartis' Rifland was approved in China in December 2017 and officially listed in July 2018 for platelet reduction in patients with chronic primary immunooplatelet altruism (ITP) patients who have been treated with glucocorticosteroids, immunoglobulin sylocutans or spleen removalPrimary immune platelet reduction is previously known as ilate platelet reduction cyanosis, its pathogenesis is due to the human body's "blood-clotting guardian" platelets based on some obtained autoimmune reasons can not reach the normal number, resulting in patientbleeding more than, unable to clotIt is reported that, as the ITP second-line treatment of the preferred solution, not only can quickly increase the number of platelets, but also the use of convenient oral methods, improve the compliance of medication, for patients to provide a new treatment optionsonly Novartis's Rifland has been approved in ChinaHowever, public information shows that, in addition to Theaikang Pharmaceuticals, Qilu Pharmaceuticals, Zhengda Tianqing and so on are also carrying out aujuPaa ethanol amine tablethuman bioequivalence testin fact, TPO-R has become one of the most popular targets for enterprise research and development, and five TPO-R drugs have been approved worldwide, namely, reeds, apophepa, Romistin, Ava poop and platelet-generatingMany Chinese companies are now joining the craze for such drugsIn April, Fosun Pharma introduced a new platelet-reducing drug, Avalquo Pa, which has been approved for use in patients with chronic liver disease in adults planning invasive surgeryNot long ago, Hengrui Pharmaceuticals also submitted a listing application in China for a new class 1 drug, Haiquupa ethanolamine tablets, which is an oral small molecule non-peptide platelet-inducing receptor (TPO-R) agonishope that these TPO-R drug research in the study will be carried out smoothly and benefit patients as soon as possible.